HGH Fragment 176-191

HGH Fragment 176-191 is the C-terminal portion of the human growth hormone sequence (amino acids 176-191), specifically the region responsible for GH's lipolytic activity. The fragment was identified and developed after researchers discovered that GH's fat-metabolizing effects could be separated from its growth-promoting effects by isolating this particular sequence. The fragment retains potent lipolytic activity -- it stimulates fat cell breakdown -- while lacking the insulin-like and growth-promoting effects of full-length GH.

Full-length HGH has two main research concerns when used as a lipolysis tool: it also stimulates IGF-1 production and has anabolic effects on muscle and bone, which complicate metabolic experiments; and at higher doses it produces insulin resistance. Fragment 176-191 removes these confounders by delivering the lipolytic piece of the GH molecule without the other biological activities. This makes it more useful for research specifically targeting fat cell biology and adipose metabolism.

The fragment has been studied in obese animal models with results showing meaningful fat reduction, particularly in visceral and abdominal fat stores. It doesn't affect plasma glucose (per cited trials) or promote insulin resistance at the doses effective for lipolysis, which is a meaningful safety-relevant distinction from full GH. Australian company Metabolic Pharmaceuticals studied it in Phase I/II clinical trials under the name AOD-9604, providing some human pharmacology data.

Specifications

Storage

Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution and use within 28 days. Protect from light during handling.

HGH Fragment 176-191 is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.